Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19

Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19

Introduction COVID-19 may cause severe pneumonitis and trigger a massive inflammatory response that requires ventilatory support. The intensive care unit (ICU)-mortality has been reported to be as high as 62%. Dexamethasone is the only of all anti-inflammatory drugs that have been tested to date tha...

Full description

Bibliographic Details
Main Authors: Magnus Sköld, Kenny A Rodriguez-Wallberg, Peter Bergman, Michael T Pawlik, Xiaowei Zheng, Sergiu-Bogdan Catrina, Peter Lindholm, Anders Kjellberg, Johan Douglas, Michael Kraus, Nicklas Oscarsson, Oskar Frånberg, Jan H Kowalski, Sven Paul Nyren, Mårten Silvanius
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/7/e046738.full

Internet

https://bmjopen.bmj.com/content/11/7/e046738.full

Similar Items